China Medical System Launches First Bispecific Antibody for Rabies in Key Hospitals
Event summary
- China Medical System's Silevimig Injection, the world's first bispecific antibody for rabies, began large-scale clinical use in multiple Chinese hospitals on September 9, 2026.
- The product received marketing approval in China in June 2026 and launched in key hospitals within two months.
- Silevimig targets dual epitopes of the rabies virus, requiring a smaller dose (0.05 mg/kg) than existing human rabies immune globulin (HRIG).
- CMS holds exclusive commercialization rights for Silevimig in mainland China and licensing rights for Asia-Pacific, Middle East, and North Africa under a 10-year agreement with Genrix Bio.
The big picture
This launch represents a significant advancement in rabies post-exposure prophylaxis, addressing critical pain points in current HRIG treatments. The product's recombinant technology and smaller dosing could improve patient compliance and accessibility, potentially reshaping the rabies treatment market in China and beyond. CMS's ability to commercialize innovative products through its academic-driven platform demonstrates its strategic focus on unmet clinical needs in specialty pharmaceuticals.
What we're watching
- Market Penetration
- Whether CMS can significantly increase the low 15% penetration rate of passive immunization products in China's 40 million annual rabies exposures.
- Regulatory Expansion
- The pace at which Silevimig gains approvals beyond China, particularly in regions covered by CMS's licensing agreement.
- Competitive Dynamics
- How existing HRIG suppliers may respond to Silevimig's advantages in dosing, administration, and production scalability.